Paulson Richard A.'s Form 4 filing
Karyopharm Therapeutics Inc. (KPTI) · filed May 15, 2026
- Accession no.
- 0001193125-26-226613
- Filed
- May 15, 2026
- Trade date
- May 13-14, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $20.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Paulson Richard A.CIK 0001804460 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 13, 2026 | Common Stock | AGrant or awardAcquired | +4,920 | $0.00 | $0 | 271,950 | Direct | |
| May 14, 2026 | Common Stock | SSaleDisposed | −2,203 | $9.50 | −$20,928.5 | 269,747 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.